This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

69.1%

Groei van de winst

91.9%

Groei van de winst per aandeel

Biotechs winstgroei	27.5%
Inkomstengroei	85.1%
Toekomstig rendement op eigen vermogen	6.6%
Dekking van analisten	Low
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Jan 21

Checking In On ChemoCentryx

Dec 15

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Oct 09

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

Sep 29

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Aug 24

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Aug 11

ChemoCentryx: CRL Less Likely

Jul 25

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Jul 11

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jun 15

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Jun 08

ChemoCentryx: CRL Likely

May 09

ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action

May 07

Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate

May 04

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

Mar 03

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 04

ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price

Jan 14

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Dec 31

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Dec 23

ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study

Dec 21

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Dec 13

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

Nov 22

ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 10

Winst- en omzetgroeiprognoses

NasdaqGS:CCXI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2024	419	68	-6	116	1
12/31/2023	190	-55	-25	-12	2
12/31/2022	64	-140	-94	-52	2
6/30/2022	37	-133	-59	-53	N/A
3/31/2022	27	-141	-54	-45	N/A
12/31/2021	32	-132	-95	-76	N/A
9/30/2021	34	-121	-112	-84	N/A
6/30/2021	22	-123	-102	-75	N/A
3/31/2021	69	-63	-101	-75	N/A
12/31/2020	65	-55	-97	-81	N/A
9/30/2020	71	-41	-89	-82	N/A
6/30/2020	76	-30	-85	-83	N/A
3/31/2020	34	-65	-81	-79	N/A
12/31/2019	36	-55	-71	-70	N/A
9/30/2019	35	-51	-66	-65	N/A
6/30/2019	34	-49	-66	-66	N/A
3/31/2019	42	-40	-44	-43	N/A
12/31/2018	43	-38	16	16	N/A
9/30/2018	90	12	36	38	N/A
6/30/2018	90	17	41	42	N/A
3/31/2018	84	14	19	20	N/A
12/31/2017	82	18	4	5	N/A
9/30/2017	31	-29	-10	-10	N/A
6/30/2017	26	-30	-5	-5	N/A
3/31/2017	20	-31	76	76	N/A
12/31/2016	12	-40	39	39	N/A
9/30/2016	7	-44	38	39	N/A
6/30/2016	3	-48	38	38	N/A
3/31/2016	N/A	-51	N/A	-41	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat CCXI de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2% ).

Winst versus markt: Er wordt verwacht dat CCXI de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat CCXI binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van CCXI ( 85.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CCXI ( 85.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CCXI zal naar verwachting over 3 jaar laag zijn ( 6.6 %).

This company listing is no longer active

ChemoCentryx Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$54.29

Consensus forecasts updated

Consensus revenue estimates fall by 13%

Consensus revenue estimates fall by 13%

Forecast to breakeven in 2024

Price target increased to US$68.43

Recent updates

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

ChemoCentryx shareholders approve $4.7B merger with Amgen

Executive VP exercised options and sold US$798k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Founder notifies of intention to sell stock

Price target decreased to US$54.29

Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire ChemoCentryx, Inc. (NasdaqGS:CCXI) for $3.7 billion.

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx: Revisiting The Investment Case

Independent Director notifies of intention to sell stock

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

ChemoCentryx Announces Changes to its Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Independent Director exercised options to buy US$212k worth of stock.

Insufficient new directors

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

Consensus revenue estimates fall by 13%

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options to buy US$905k worth of stock.

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

ChemoCentryx, Inc Announces EU Approval of Tavneos® (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Consensus revenue estimates fall by 13%

Founder exercised options and sold US$1.7m worth of stock

Forecast to breakeven in 2024

Independent Director exercised options and sold US$817k worth of stock

Checking In On ChemoCentryx

Founder exercised options to buy US$1.6m worth of stock.

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Price target increased to US$68.43

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Consensus forecasts updated

ChemoCentryx: CRL Less Likely

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed against ChemoCentryx, Inc

Executive VP & COO recently bought US$120k worth of stock

Consensus revenue estimates fall to US$38.2m

ChemoCentryx: CRL Likely

ChemoCentryx Announces Results of U.S. Food and Drug Administration Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

Price target decreased to US$78.75

ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against ChemoCentryx, Inc

Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate

First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)

Director recently sold US$1.8m worth of stock

ChemoCentryx, Inc Appoint Susan M. Kanaya to the Board of Directors

Analysts update estimates

Senior VP exercised options and sold US$1.9m worth of stock

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

ChemoCentryx, Inc. Appoints Tausif Butt as Executive Vice President and Chief Operating Officer